Table 3.
Predictors of clinical remission and endoscopic remission in all patients with CD undergoing UST use.
| Predictors of treatment outcomes | Univariate analysis | p Value | Multivariable analysis | p Value |
|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||
| Clinical remission | ||||
| Male gender | 0.590 (0.337–1.035) | 0.066 | 0.527 (0.260–1.067) | 0.075 |
| Early UST use | 0.122 (0.068–0.219) | <0.001 | 0.105 (0.049–0.225) | <0.001 |
| Stricturing/penetrating phenotype | 1.690 (1.011–2.828) | 0.045 | 0.732 (0.332–1.617) | 0.441 |
| Active perianal disease | 2.783 (1.639–4.725) | <0.001 | 4.742 (2.357–9.538) | <0.001 |
| Previous intestinal resection | 3.206 (1.735–5.924) | <0.001 | 2.382 (0.927–6.121) | 0.071 |
| Biologics exposure | 3.087 (1.816–5.248) | <0.001 | 1.364 (0.692–2.688) | 0.370 |
| Severe disease | 1.705 (0.949–3.064) | 0.074 | 1.024 (0.472–2.221) | 0.953 |
| CRP/ALB | 1.501 (1.052–2.141) | 0.025 | 1.884 (1.182–3.001) | 0.008 |
| Endoscopic remission | ||||
| Male gender | 0.548 (0.282–1.067) | 0.077 | 0.604 (0.295–1.239) | 0.169 |
| Early UST use | 0.306 (0.167–0.559) | <0.001 | 0.400 (0.205–0.781) | 0.007 |
| Biologics exposure | 2.957 (1.622–5.389) | <0.001 | 1.761 (0.894–3.470) | 0.102 |
| Severe disease | 3.782 (1.818–7.870) | <0.001 | 3.312 (1.541–7.116) | 0.002 |
Variables entered in the multivariable models before backward selection was performed included those with p < 0.1. For clinical and endoscopic remission, variables included gender, early UST use, disease location, stricturing/penetrating phenotype, active perianal disease, extra-intestinal manifestations, previous intestinal resection, previous or current smoking, biologics exposure, severe disease, body mass index, and CRP/ALB.
ALB, albumin; CD, Crohn’s disease; CRP, C-reactive protein; UST, Ustekinumab.